PBM
PSYENCE BIOMEDICAL LTD.
$3.60
+2.56%
$7.8M
No data for this timeframe.
Vol
Market Cap$7.8M
Cap SizeNano Cap
Reddit Sentiment82° Bullish
Press Releases2
Recent Activity
May 15, 2026
other
Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing
<p align="justify">NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Psyence BioMed Ltd. (Nasdaq: PBM) (“
Apr 23, 2026
Press
Psyence Biomedical Ltd. (PBM) announced the first patient dosed in its Phase IIb clinical trial evaluating NPX-5, a natu
Impact 7/10
Apr 20, 2026
Press
Psyence Biomedical Ltd. announced advancements in its vertically integrated ibogaine supply chain through its subsidiary
Impact 3/10
Reddit Sentiment
82°▼
Bullish
Bearish
Neutral
Bullish
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
No SEC filing reports analyzed yet. Reports are generated when new filings are detected and processed by the LLM pipeline.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
82°
Bullish
Bearish
Neutral
Bullish
18 mentions
14 bullish
0 bearish
17 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Apr 24, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 24, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 24, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 24, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 20, 2026 | 2 | 67° Warm | 2 | 0 | 2 |
| Apr 20, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 19, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| Apr 19, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| Apr 18, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 18, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 17, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 16, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 16, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 16, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 16, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 16, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| Mar 16, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
Will PBM spike Monday and why?
▲ 1
💬 1
⚡ 0.5
🚨 $PBM YOLO 🚨 Get your moon tickets. The White House is pumping psychedelics and this micro-cap is about to 🚀 the moon! 🍄
▲ 1
💬 0
⚡ 0.5
17 APRIL 2026 WHAT ARE THE BIGGEST WINNERS PRE-MARKET ?
▲ 1
💬 1
⚡ 0.5
May 15, 2026
other
Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing
<p align="justify">NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Psyence BioMed Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceut
Apr 23, 2026
fda
Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder
Dosing initiates clinical evaluation of NPX-5, a GMP-compliant, nature-derived psilocybin candidate across an expanded Australian site network <pre>Do
Apr 20, 2026
contract
Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source
Through its investment in and collaboration with PsyLabs, the Company has established a GMP-compliant, pharmaceutical-grade supply chain <pre>Through
Apr 20, 2026
short_interest
FTD: PBM — 201,345 shares ($1.5M) failed to deliver
Settlement: 20260420, Price: $7.60, FTD Value: $1,530,222, PSYENCE BIOMEDICAL LTD COM NO
Apr 17, 2026
other
Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine
Company highlights global leadership in GMP ibogaine manufacturing and commitment to ethically sourced supply <pre>Company highlights global leadershi
Apr 17, 2026
short_interest
FTD: PBM — 158,256 shares ($0.9M) failed to deliver
Settlement: 20260417, Price: $5.87, FTD Value: $928,962.72, PSYENCE BIOMEDICAL LTD COM NO
Apr 16, 2026
short_volume
Short Volume: PBM — 57.7% short (11.8M / 20.4M)
Short: 11,765,167 | Exempt: 112,439 | TRF Vol: 20,386,724 | Short Ratio: 57.7% | Off-exchange volume (dark pool + OTC)
Apr 8, 2026
other
Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5–Supported Clinical Activities
Expansion supports accelerated enrollment and advancement of the Company’s lead clinical asset <pre>Expansion supports accelerated enrollment and adva
Mar 11, 2026
other
Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone
“The strongest companies are built on the right foundations long before their moment arrives,” says CEO Jody Aufrichtig <pre>“The strongest companies
Mar 3, 2026
other
Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial
<p align="justify">NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biophar